title: Comparison of enoxaparin and unfractionated heparin in coronary angioplasty.
abstract: BACKGROUND
  Recent studies have shown that enoxaparin may be equally as safe and effective as unfractionated heparin during a coronary angioplasty procedure. The aim of this study was to investigate whether enoxaparin can be used effectively and safely in place of unfractionated heparin in patients undergoing emergency or programmed coronary angioplasty, regardless of the use of platelet glycoprotein IIb/IIIa inhibitors.
  
  
  METHODS
  We compared two series of consecutive patients, who received unfractionated heparin (n = 217) or enoxaparin (n = 116) during emergency or programmed angioplasty, regardless of age, weight, renal function and the coadministration of platelet glycoprotein IIb/IIIa inhibitors. In the patients who received enoxaparin the arterial sheaths were removed immediately after the procedure.
  
  
  RESULTS
  There were no significant differences between the two groups as regards clinical characteristics or risk factors for coronary artery disease. During a 30-day follow up no major adverse cardiac events were observed (death, myocardial infarction, target vessel revascularisation). Multivariate logistic regression analysis showed no correlation between the anticoagulant used and the occurrence of major cardiac events in the two groups of patients (log odds ratio = -9.46, p = 0.89), after controlling for age, sex, administration of platelet glycoprotein IIb/IIIa inhibitors, number of coronary lesions, number of stents used, clinical picture and risk factors for coronary artery disease. As regards the development of haematoma in the groin, the only significant independent predictive factor for this was the coadministration of platelet glycoprotein IIb/IIIa inhibitors.
  
  
  CONCLUSIONS
  The use of enoxaparin in coronary angioplasty is safe, effective and allows faster removal of sheaths and mobilisation of the patient.
authors.affiliation: Cardiology Department, Athens Euroclinic, Athens, Greece.
authors.forename: Socrates
authors.initials: S
authors.lastname: Korovesis
authors.forename: Evangelia
authors.initials: E
authors.lastname: Karvouni
authors.forename: Ilias
authors.initials: I
authors.lastname: Karabinos
authors.forename: Eleftherios
authors.initials: E
authors.lastname: Giazitzoglou
authors.forename: Anastasios
authors.initials: A
authors.lastname: Papadopoulos
authors.forename: Demosthenes
authors.initials: D
authors.lastname: Katritsis
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D015331:Cohort Studies; D017023:Coronary Angiography; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004632:Emergency Medical Services; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use*; D011336:Probability; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D015607:Stents; D016896:Treatment Outcome
chemical_list: D017984:Enoxaparin; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin